---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-211456"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:18:57.633026+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha raises $150M PIPE; first Rett patient data shows clinical improvement

## Summary
- Gross proceeds of $150M from PIPE: 122.4M shares at $0.90/share and 44.3M pre-funded warrants.
- Q2 2023 net loss $24.6M ($0.38/sh); cash $45.1M at June 30; PIPE extends runway into Q3 2025.
- First adult Rett patient dosed in REVEAL trial: TSHA-102 well-tolerated, no SAEs at 6 weeks.
- At 4 weeks, CGI-I score of 2 (much improved), RSBQ improved 23 points, patient gained ability to sit unassisted and hold objects.
- FDA cleared IND for TSHA-102 in pediatric Rett; CTA submitted to UK MHRA.

## SEC filing metadata
- accession: 0001193125-23-211456
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/d497848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-211456
- JSON: https://secwatch.observer/filing/0001193125-23-211456.json
- Plain text: https://secwatch.observer/filing/0001193125-23-211456.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, the Company reported financial results and business highlights for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm
- Material Agreements
  Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at approximately $150.0 million (effective 2023-08-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and other accredited investors
  - Value: approximately $150.0 million
  - Effective: 2023-08-14
  source text: On August 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional and other accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 122,412,376 shares (the “ Shares ”) of the Company’s common stock, par value $0.00001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 44,250,978 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.